Image-guided intensity modulated radiotherapy with helical tomotherapy for postoperative treatment of high-risk oral cavity cancer.
BACKGROUND
The aim of this study was to assess the treatment results and toxicity profiles of helical tomotherapy (HT) for postoperative high-risk oral cavity cancer.


METHODS
From December 6, 2006 through October 9, 2009, 19 postoperative high-risk oral cavity cancer patients were enrolled. All of the patients received HT with (84%) or without (16%) chemotherapy.


RESULTS
The median follow-up time was 17 months. The 2-year overall survival, disease-free survival, locoregional control, and distant metastasis-free rates were 94%, 84%, 92%, and 94%, respectively. The package of overall treatment time > 13 wk, the interval between surgery and radiation ≤ 6 wk, and the overall treatment time of radiation ≤ 7 wk was 21%, 84%, and 79%, respectively. The percentage of grade 3 mucositis, dermatitis, and leucopenia was 42%, 5% and 5%, respectively.


CONCLUSIONS
HT achieved encouraging clinical outcomes for postoperative high-risk oral cavity cancer patients with high compliance. A long-term follow-up study is needed to confirm these preliminary findings.
Department of Radiation Oncology, Far Eastern Memorial Hospital, Taipei, Taiwan.
Chen-Hsi
CH
Hsieh
Ying-Shiung
YS
Kuo
Li-Jen
LJ
Liao
Kawang-Yu
KY
Hu
Shih-Chiang
SC
Lin
Le-Jung
LJ
Wu
Yu-Chin
YC
Lin
Yu-Jen
YJ
Chen
Li-Ying
LY
Wang
Yen-Ping
YP
Hsieh
Shoei Long
SL
Lin
Chun-Yi
CY
Chen
Chien-An
CA
Chen
Pei-Wei
PW
Shueng
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009055:Mouth / Q000187:drug effects / Q000528:radiation effects* / Q000601:surgery; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D052016:Mucositis / Q000209:etiology; D011182:Postoperative Care; D011855:Radiodermatitis / Q000209:etiology; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods*; D012307:Risk Factors; D036542:Tomography, Spiral Computed / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents
Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1639-44
15590196
Radiother Oncol. 2001 Aug;60(2):137-45
11439208
Int J Radiat Oncol Biol Phys. 1993 Apr 30;26(1):3-11
8482629
Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1332-41
17276613
Head Neck. 2008 Apr;30(4):503-8
18098310
Med Phys. 1993 Nov-Dec;20(6):1709-19
8309444
Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):693-700
14529773
Acta Otorhinolaryngol Belg. 1999;53(3):271-5
10635407
Int J Radiat Oncol Biol Phys. 1989 Jan;16(1):25-36
2912947
Radiother Oncol. 1997 Apr;43(1):29-37
9165134
N Engl J Med. 2004 May 6;350(19):1937-44
15128893
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):28-42
15093896
Radiother Oncol. 2000 Aug;56(2):135-50
10927132
Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):312-21
12527043
Oral Oncol. 2009 Jun;45(6):505-10
18805047
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):715-21
19879069
J Clin Oncol. 2009 Oct 1;27(28):4727-32
19720915
Radiat Oncol. 2007 Apr 12;2:16
17430599
Plast Reconstr Surg. 2005 Dec;116(7):1845-55
16327594
Head Neck. 2004 Nov;26(11):984-94
15459927
Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):137-48
9300748
Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):571-8
11597795
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1174-84
12128118
Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1096-103
18707827
N Engl J Med. 2004 May 6;350(19):1945-52
15128894